| Literature DB >> 31819630 |
Ran Zhang1,2, Changbin Wang2,3, Kai Cui3,4, Yicong Chen1,2, Fenghao Sun2,5, Xiaorong Sun4, Ligang Xing2.
Abstract
PURPOSE: The imaging features of patients with early-stage non-small cell lung cancer (NSCLC) receiving stereotactic body radiotherapy (SBRT) are crucial for the decision-making process to establish a treatment plan. The purpose of this study was to predict the clinical outcomes of SBRT from the textural features of pretreatment computed tomography (CT) images. PATIENTS AND METHODS: Forty-one early-stage NSCLC patients who received SBRT were included in this retrospective study. In total, 72 textural features were extracted from the pretreatment contrast-enhanced CT images. Survival analysis was used to identify high-risk groups for progression-free survival (PFS) and disease-specific survival (DSS). Receiver operating characteristic (ROC) curve analysis was utilized to estimate the diagnostic abilities of the textural parameters. Univariable and multivariable Cox regression analyses were performed to evaluate the predictors of PFS and DSS.Entities:
Keywords: NSCLC; clinical outcomes; computed tomography imaging; non-small cell lung cancer; stereotactic body radiation therapy; textural analysis
Year: 2019 PMID: 31819630 PMCID: PMC6883938 DOI: 10.2147/CMAR.S220587
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Patient Characteristics
| Patient Characteristic | n | % |
|---|---|---|
| Age | 71 (53–84) | |
| Sex | ||
| Male | 30 | 73.2% |
| Female | 11 | 26.8% |
| T Stage(n) | ||
| T1 | 31 | 75.6% |
| T2 | 10 | 24.4% |
| Smoking | 23 | 56.1% |
| Histology (n) | ||
| Squamous | 8 | 19.5% |
| Adeno | 23 | 56.1% |
| Unknown | 10 | 24.4% |
| Biological effective dose | ||
| 110–120 Gy | 20 | 48.8% |
| 100–110 Gy | 5 | 12.2% |
| 90–100 Gy | 5 | 12.2% |
| 75–90 Gy | 11 | 26.8% |
| Location | ||
| Central | 13 | 31.7% |
| Peripheral | 28 | 68.3% |
Figure 1Representative computed tomography image of a 60-year-old man with lung adenocarcinoma. (A) A tumor in the left lobe was chosen to delineate region of interest. (B) One radiologist delineated the region of interest, which is shown in green outline.
Kaplan-Meier Analysis Of Progression-Free Survival And Disease-Specific Survival
| Parameter | PFS | DSS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cut-off | Low risk | High risk | P | Cut-off | Low risk | High risk | P | |||||
| n | m | n | m | n | m | n | m | |||||
| Entropy | 6.91 | 5 | 27.9 | 8 | 17.1 | 0.003* | 6.91 | 2 | 33.8 | 3 | 29.2 | 0.255 |
| SAM | 1.64×10−3 | 6 | 26.9 | 7 | 20.1 | 0.040* | 4.96×10−3 | 3 | 32.9 | 2 | 26.4 | 0.012 |
| HILRE | 9.25×104 | 6 | 28.5 | 7 | 17.6 | 0.046* | 6.48×104 | 1 | 34 | 4 | 29.7 | 0.280 |
| LRE | 22.00 | 5 | 29.2 | 8 | 19.5 | 0.042* | 17.43 | 1 | 34.3 | 4 | 28.2 | 0.109 |
| Contrast | 3.03×105 | 1 | 28.3 | 12 | 23.7 | 0.111 | 9.77×105 | 1 | 34.8 | 4 | 25.6 | 0.008* |
| LIZE | 1.93×10−3 | 0 | NA | 13 | NA | 0.236 | 2.50×10−3 | 3 | 33.1 | 2 | 21.5 | 0.010* |
| Coarseness | 1.47×10−3 | 1 | 28.3 | 12 | 23.9 | 0.137 | 2.22×10−3 | 2 | 33.8 | 3 | 24.4 | 0.017* |
| LNE | 5.03 | 5 | 26.9 | 8 | 23.4 | 0.280 | 7.60 | 2 | 33.7 | 3 | 25.2 | 0.046* |
Note: *P<0.05.
Abbreviations: PFS, progression-free survival; DSS, disease-specific survival; SAM, second angular moment; HILRE, high-intensity long-run emphasis; LRE, long-run emphasis; LIZE, low-intensity zone emphasis; LNE, large number emphasis; n, numbers of events; m: mean survival.
Figure 2Survival curves for PFS and DSS. PFS of the subgroups determined by entropy (A), SAM (B), HILRE (C), and LRE (D). DSS of the subgroups determined by contrast (E), LIZE (F), coarseness (G), and LNE (H).
Abbreviations: PFS, progression-free survival; DSS, disease-specific survival; SAM, second angular moment; HILRE, high-intensity long-run emphasis; LRE, long-run emphasis; LIZE, low-intensity zone emphasis; LNE, large number emphasis.
ROC Analysis Of LR, LNM, DM, PFS And DSS
| Parameter | LR | LNM | DM | PFS | DSS |
|---|---|---|---|---|---|
| Entropy | 0.600(0.304–0.896) | 0.218(0.067–0.369) | 0.646(0.447–0.845) | 0.583(0.302–0.864) | |
| SAM | 0.294(0.078–0.511) | 0.314(0.042–0.586) | 0.365(0.167–0.564) | 0.489(0.180–0.797) | |
| HILRE | 0.378(0.134–0.621) | 0.681(0.475–0.887) | 0.731(0.471–0.990) | 0.593(0.409–0.778) | 0.600(0.377–0.823) |
| LRE | 0.356(0.106–0.605) | 0.662(0.423–0.901) | 0.571(0.378–0.765) | 0.583(0.332–0.824) | |
| Contrast | 0.289(0.092–0.486) | 0.667(0.444–0.890) | 0.541(0.353–0.729) | 0.700(0.476–0.924) | |
| LIZE | 0.689(0.439–0.939) | 0.462(0.268–0.656) | 0.103(0.007–0.198) | 0.486(0.296–0.676) | 0.406(0.156–0.655) |
| Coarseness | 0.386(0.168–0.603) | 0.154(0.041–0.267) | 0.470(0.280–0.660) | 0.317(0.069–0.564) | |
| LNE | 0.267(0.030–0.503) | 0.552(0.313–0.792) | 0.497(0.295–0.700) | 0.594(0.298–0.891) |
Note: Significant values are printed in bold.
Abbreviations: LR, local recurrence; LNM, lymph node metastasis; DM, distant metastasis; PFS, progression-free survival; DSS, disease-specific survival; SAM, second angular moment; HILRE, high-intensity long-run emphasis; LRE, long-run emphasis; LIZE, low-intensity zone emphasis; LNE, large number emphasis.
Univariable And Multivariable Survival Analyses Of PFS And DSS
| Parameter | PFS | DSS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||
| HR | P | HR | P | HR | P | HR | P | |
| Age | 0.999(0.936–1.067) | 0.987 | 1.046(0.925–1.1.83) | 0.470 | ||||
| Sex | 0.941(0.288–3.077) | 0.920 | 0.025(0.000–65.406) | 0.359 | ||||
| Tumor size | 1.343(0.630–2.861) | 0.455 | 1.737(0.469–6.433) | 0.408 | ||||
| T Stage | 2.147(0.619–7.456) | 0.229 | 4.004(0.808–19.835) | 0.089 | 1.332(0.143–12.405) | 0.801 | ||
| Smoking | 2.512(0.766–8.241) | 0.129 | 4.263 (0.470–38.692) | 0.198 | ||||
| Location | 2.194(0.733–6.562) | 0.160 | 1.817(0.547–6.0330) | 0.329 | 3.836(0.638–23.076) | 0.142 | ||
| Entropy | 3.440(0.703–16.835) | 0.127 | 1.801(0.178–18.226) | 0.618 | ||||
| SAM | / | 0.644 | / | 0.606 | ||||
| HILRE | / | 0.691 | / | 0.746 | ||||
| LRE | 1.028(0.992–1.065) | 0.128 | 1.026(0.981–1.073) | 0.258 | 1.030(0.972–1.092) | 0.323 | ||
| Contrast | / | 0.869 | / | 0.757 | ||||
| LIZE | / | 0.576 | / | 0.282 | ||||
| Coarseness | / | 0.284 | / | 0.355 | ||||
| LNE | 1.010(0.908–1.124) | 0.852 | 1.067(0.921–1.236) | 0.387 | ||||
| Operable | / | 0.355 | / | 0.533 | ||||
| Histology | 0.645(0.324–1.284) | 0.212 | 0.763(0.268–2.174) | 0.612 | ||||
| BED | 0.665(0.223–1.984) | 0.464 | 1.057(0.176–6.347) | 0.952 | ||||
Note: Significant values are printed in bold.
Abbreviations: PFS, progression-free survival; DSS, disease-specific survival; SAM, second angular moment; HILRE, high-intensity long-run emphasis; LRE, long-run emphasis; LIZE, low-intensity zone emphasis; LNE, large number emphasis; BED, biological effective dose.